The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: A systematic review

Vernooij, Flora; Heintz, Peter; Witteveen, Els O.; Graaf, Yolanda van der

doi:10.1016/j.ygyno.2007.02.030

Cited by 242 publications

(147 citation statements)

References 32 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Treatment quality is influenced by physician-related factors. Several studies have demonstrated superior outcomes for women treated by surgical specialists and high-volume surgeons (Junor et al, 1999;Carney et al, 2002;Elit et al, 2002;Earle et al, 2006;Goff et al, 2006Goff et al, , 2007Paulsen et al, 2006b;Vernooij et al, 2007). In an analysis of over 3000 patients, those operated on by gynaecologic oncologists were more likely to undergo surgical cytoreduction and had improved outcomes .…”

Section: Discussionmentioning

confidence: 99%

“…In an analysis of over 3000 patients, those operated on by gynaecologic oncologists were more likely to undergo surgical cytoreduction and had improved outcomes . Likewise, patients who were operated on at high-volume facilities and teaching hospitals are more likely to undergo comprehensive surgical staging and cytoreduction, and have better survival than those treated at smaller and non-teaching hospitals (Tingulstad et al, 2003;Paulsen et al, 2006b;Vernooij et al, 2007). However, many patients with OC do not receive care from surgical specialists or at large volume facilities (Carney et al, 2002;Bristow et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival

et al. 2008

View full text Add to dashboard Cite

Given the survival benefits of adjuvant chemotherapy for advanced ovarian cancer (OC), we examined the associations of survival with the time interval from debulking surgery to initiation of chemotherapy and with the duration of chemotherapy. Among patients X65 years with stages III/IV OC diagnosed between 1991 and 2002 in the Surveillance, Epidemiology, and End Results-Medicare database, we developed regression models of predictors of the time interval from surgery to initiation of chemotherapy and of the total duration of chemotherapy. Survival was examined with Cox proportional hazards models. Among 2558 patients, 1712 (67%) initiated chemotherapy within 6 weeks of debulking surgery, while 846 (33%) began treatment 46 weeks. Older age, black race, being unmarried, and increased comorbidities were associated with delayed initiation of chemotherapy. Delay of chemotherapy was associated with an increase in mortality (hazard ratio (HR) ¼ 1.11; 95% CI, 1.0 -1.2). Among 1932 patients in the duration of treatment analysis, the 1218 (63%) treated for 3 -7 months had better survival than the 714 (37%) treated for p3 months (HR ¼ 0.84; 95% CI, 0.75 -0.94). This analysis represents one of the few studies describing treatment delivery and outcome in women with advanced OC. Delayed initiation and early discontinuation of chemotherapy were common and associated with increased mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Women with malignant adnexal masses require radical cytoreductive surgery by a specialist surgeon with expertise in gynaecological oncology [5][6][7], whilst benign masses may be either managed conservatively or undergo resection under the care of a general gynaecologist. Further, women with suspected malignancy may require transfer of their care to a specialist institution.…”

Section: Introductionmentioning

confidence: 99%

ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach

Forstner²,

et al. 2009

View full text Add to dashboard Cite

ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach Abstract A significant proportion of adnexal masses detected by sonography are indeterminate. Either their organ of origin is uncertain or it is unclear whether their nature is benign or malignant. MR imaging of the sonographically indeterminate adnexal mass can resolve most of these uncertainties. Most indeterminate masses result from common benign conditions and women with such masses can avoid unnecessary or inappropriate surgery. For the minority of women whose masses are malignant, use of MR imaging rather than a 'wait and watch' strategy of repeat ultrasound (US) results in a more timely diagnosis. There are simple diagnostic steps in the MR imaging assessment which direct an algorithmic and problem-solving approach based on signal characteristics and morphology. MR imaging should provide a more timely diagnosis and, thereby, guide the management of the patient with reduced costs of investigation and treatment.

show abstract

“…[7][8][9][10] Optimal cytoreduction rates range from 40-90%, with a higher rate of optimal cytoreduction in patients treated by gynecologic oncologists and when surgery is performed in high-volume institutions. 11 In order to prevent under treatment of a substantial number of patients, an accurate preoperative assessment on resectibility and operative risk is therefore essential to Division of Gynaecologic Oncology, Department of Obstetrics and Gynecology, Mazumdar Shaw Health Center, Bangalore, Karnataka, India guarantee proper decision making and management of these patients. 12,13 Computed tomography (CT) scans have been used extensively as a diagnostic and surveillance tool in patients with ovarian carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Comparative study of pre-operative CT scan and per-operative findings in carcinoma ovary

Suchitra¹,

P.²,

Kalla³

et al. 2015

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: A systematic review

Cited by 242 publications

References 32 publications

Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival

Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival

ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach

Comparative study of pre-operative CT scan and per-operative findings in carcinoma ovary

Contact Info

Product

Resources

About